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Abstract
Non-syndromic kyphosis is a common disorder that is associated with significant morbidity
and has a strong genetic involvement; however, the causative genes remain to be identified,
as such studies are hampered by genetic heterogeneity, small families and various modes
of inheritance. To overcome these limitations, we investigated 12 week old progeny of mice
treated with the chemical mutagen N-ethyl-N-nitrosourea (ENU) using phenotypic assess-
ments including dysmorphology, radiography, and dual-energy X-ray absorptiometry. This
identified a mouse with autosomal recessive kyphosis (KYLB). KYLB mice, when compared
to unaffected littermates, had: thoraco-lumbar kyphosis, larger vertebrae, and increased
body length and increased bone area. In addition, female KYLB mice had increases in bone
mineral content and plasma alkaline phosphatase activity. Recombination mapping local-
ized the Kylb locus to a 5.5Mb region on chromosome 15A1, which contained 51 genes,
including the natriuretic peptide receptor 3 (Npr3) gene. DNA sequence analysis of Npr3
identified a missense mutation, Tyr209Asn, which introduced an N-linked glycosylation con-
sensus sequence. Expression of wild-type NPR3 and the KYLB-associated Tyr209Asn
NPR3 mutant in COS-7 cells demonstrated the mutant to be associated with abnormal N-
linked glycosylation and retention in the endoplasmic reticulum that resulted in its absence
from the plasma membrane. NPR3 is a decoy receptor for C-type natriuretic peptide (CNP),
which also binds to NPR2 and stimulates mitogen-activated protein kinase (MAPK) signal-
ing, thereby increasing the number and size of hypertrophic chondrocytes. Histomorpho-
metric analysis of KYLB vertebrae and tibiae showed delayed endochondral ossification
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and expansion of the hypertrophic zones of the growth plates, and immunohistochemistry
revealed increased p38 MAPK phosphorylation throughout the growth plates of KYLB verte-
brae. Thus, we established a model of kyphosis due to a novel NPR3 mutation, in which loss
of plasma membrane NPR3 expression results in increased MAPK pathway activation,
causing elongation of the vertebrae and resulting in kyphosis.
Introduction
Kyphosis, a common disorder in humans, is characterized by excessive curvature of the verte-
bral column [1] that can occur at any age. Kyphosis may result from trauma, metabolic disor-
ders, neuromuscular diseases, vertebral fusion [2, 3], and osteoporotic fractures [4]. In
addition, genetic diseases may give rise to kyphosis in isolation or in association with other
developmental abnormalities, such as Larsen Syndrome (OMIM: #150250), due to dominant
mutations in FLNB [5, 6]. The most common form of adolescent isolated kyphosis, referred to
as Scheuermann disease (OMIM: %181440), affects>8% of the population and may be inher-
ited in an autosomal dominant manner, although the causative gene(s) remains to be identi-
fied [7–10]. A study of adult female twins reported the heritability of thoracic kyphosis to be
>60%, thereby demonstrating that kyphosis has a strong genetic component [11].
Identification of the genetic abnormalities associated with isolated forms of kyphosis has
been hampered by genetic heterogeneity, small families that do not enable localization of the
disease locus by linkage studies, variable modes of inheritance, and gene-environment interac-
tions that may modify vertebral phenotypes [6]. In addition, studies of the underlying mecha-
nisms of kyphosis have been hampered by a lack of suitable models with relevance to kyphosis
in humans.
To overcome these limitations and facilitate further mechanistic studies, we sought to estab-
lish mouse models for kyphosis using phenotypic assessments including dysmorphology, radi-
ography and dual energy X-ray absorptiometry (DXA), of progeny of mice treated with the
chemical mutagen N-ethyl-N-nitrosourea (ENU). ENU is a powerful alkylating agent that
introduces mainly point mutations into the genome, and has been successfully used to identify
mouse models for many different disorders, including skeletal dysplasias [12, 13], deafness
[14], and type 2 diabetes [15, 16]. For example, an ENU-induced mutation in the collagen 2
alpha 1 (Col2a1) gene has been described to result in spondyloepiphyseal dysplasia congenita
(SEDC), with affected mice displaying short humeri, abnormal vertebrae and disorganized
growth plates [17]. Here, we report studies of an ENU-induced mouse model for autosomal
recessive kyphosis, designated KYLB, that harbors a novel mutation in natriuretic peptide
receptor 3 (Npr3).
Materials and Methods
Ethics statement
All animal studies were carried out using guidelines issued by the Medical Research Council in
’Responsibility in the Use of Animals for Medical Research’ (July 1993) and under Home
Office Project License Number 30/2433. Experiments were approved by the Medical Research
Council Harwell and UK Home Office ethics committees.
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Health-F2-2008-200800) (CTE, MAN, NYL, RVT).
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preparation of the manuscript.
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Generation of mutant mice
Male BALB/c mice were treated with ENU and mated with untreated BALB/c female mice
[18]. The male progeny (G1) were subsequently mated with normal BALB/c females to gener-
ate G2 progeny. The female G2 progeny were then backcrossed to their G1 fathers, thereby
facilitating autosomal recessive traits to manifest in the resulting G3 progeny [18]. These G3
progeny were assessed for skeletal phenotypes using dysmorphology for gross anatomical
defects and radiography for bone abnormalities. Mice with phenotypic abnormalities were
bred onto the C57BL/6J background for inheritance testing and mapping studies. Mice were
fed an expanded rat and mouse no. 3 breeding diet (Special Diets Services, Witham, UK) con-
taining 1.15% calcium, 0.82% phosphate and 4088.65 units/kg vitamin D, and given water ad
libitum.
Dysmorphology, radiography and dual-energy X-ray absorptiometry
(DXA)
A simple dysmorphology screen based on observation for any gross anatomical changes was
used to monitor all mice at 3–6 weeks of age, as previously described [12]. Anaesthetised mice
were subjected to digital radiography at 26kV for 3 seconds using a Faxitron MX-20 digital X-
ray system (Faxitron X-ray Corporation, Lincolnshire, USA) [17] and DXA using a Lunar PIX-
Imus densitometer (GE Healthcare, Chalfont St Giles, UK) [19]. X-ray images were processed
using the DicomWorks software (http://www.dicomworks.com/) [17] and DXA images were
processed using the PIXImus software [19].
Skeletal preparation and staining with Alcian blue and Alizarin red
After removal of skin, skeletons were fixed in 95% ethanol, stained with Alcian blue (8GX) for
24 hours, differentiated in 95% alcohol, treated with 1% potassium hydroxide for 2 days,
washed overnight in running tap water, stained in aqueous Alizarin red S for 2 hours, washed
in running tap water for 30 minutes, decolourised in 20% glycerine/1% potassium hydroxide
for 1 week, and dehydrated through graded alcohols, as described [17]. Images were acquired
using a Nikon D3 camera [17]. Femoral lengths were measured using electronic calipers after
dissection.
Mapping, DNA sequencing and genotyping
Genomic DNA was extracted from ear or tail biopsies as described [17]. For genome-wide
mapping, DNA was amplified by PCR using a panel of 91 single nucleotide polymorphic
(SNP) loci arranged in chromosome sets, and the products were analysed by pyrosequencing
[20]. DNA sequencing analysis was undertaken using gene-specific primers that amplified the
exons and adjacent splice sites and BigDye terminator reagents with products analysed on an
ABI3100 sequencer (Life Technologies, Carlsbad, CA, USA) [17]. Genotyping was performed
by PCR amplification of exon 1 using Taq PCR Mastermix (Qiagen, Crawley, UK) and the
PCR products digested with restriction endonuclease Tsp509I, and separated by agarose gel
electrophoresis. Images were acquired using a GelDoc™ UV transilluminator (Bio-Rad, Hemel
Hempstead, UK) [17].
In vitro expression studies of wild-type and mutant NPR3
Three ENU-induced NPR3 mutants, which are associated with kyphosis, comprising the
Tyr209Asn mutation identified by this study, and the His168Asn and Ile384Asn mutations
identified by previous studies [21, 22] were investigated, as follows. A full length wild-type
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Npr3 cDNA was obtained from an IMAGE clone (ID: 4019152, Geneservice) and sub-cloned
in-frame into the EcoRI/SacII sites of the enhanced green fluorescent protein (pEGFP)-N1
plasmid (Clontech, Saint-Germain-en-Laye, France) in two steps. In the first step, an EcoRI/
PstI fragment containing 1434bp of the 1611bp of Npr3 coding cDNA (5’ end) was digested
from the IMAGE clone (5’ end) and inserted into pEGFP-N1 using corresponding restriction
sites. In the second step, a 648bp PCR product was amplified from the IMAGE clone using Pfu
Ultra™ II DNA polymerase (Agilent Technologies, Stockport, UK) to include the internal PstI
site, and the remaining 3’ Npr3 cDNA, whilst also introducing a 3’ overhang containing a SacII
site by using the primers Npr3-992F (ACTGAGGACCGTGAAACCTG),and SacII-Npr3-1640R
(CCGCGGAGCCACCGAAAAATGTGATCT). This PCR product was subcloned into the PstI/
SacII sites of the pEGFP-N1 containing the 5’ fragment of Npr3. Npr3 mutations were intro-
duced using site-directed mutagenesis with the following forward primers: Tyr209Asn: 5’-
AACTCGAGAGGAACTGTAATTTCACC-3’; His168Asn: 5’-GACACGGAATACTCGAACCTCA
CGCGCGTG-3’; and Ile384Phe: 5’-GATGGGGGGAAAATCTTCCAGCAGACTTGG-3’; and
their reverse complement primers. Constructs were verified by DNA sequencing. The cDNA
constructs (1μg of each) were transfected into COS-7 cells using jetPEI reagent (Source Biosci-
ence, Nottingham, UK) and Western blot and immunofluorescence analyses undertaken.
Western blot analyses were performed using untreated or enzymatically deglycosylated lysates
from transfected COS-7 cells [19]. Briefly, lysates were boiled for 10 min in denaturing buffer
(0.5% SDS, 1% 2-mercaptoethanol), and treated with endoglycosidase (Endo) H (New England
Biolabs, Ipswich, UK) [19]. Samples were separated by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE), electroblotted onto nitrocellulose membrane (GE Health-
care, Little Chalfont, UK), probed with rabbit anti-GFP polyclonal antibody (Santa Cruz Bio-
technology, Santa Cruz, USA) followed by HRP-conjugated goat anti-rabbit IgG (Bio-Rad,
Hemel Hempstead, UK) and ECL detection (GE Healthcare, Little Chalfont, UK), as described
previously [19]. The membrane was stripped and re-probed with mouse 12G10 anti-alpha-
tubulin antibody (Developmental Studies Hybridoma Bank, University of Iowa) and HRP-
conjugated goat anti-mouse IgG (Bio-Rad) as a loading control [19]. For immunofluorescence
studies, transfected cells cultured on glass coverslips were fixed, permeabilized, blocked and
incubated with mouse anti-Golgi matrix protein 130 (GM130) antibody (BD Bioscience,
Oxford, UK) or mouse anti-PDI antibody (Enzo Life Science, Exeter, UK), followed by Alexa-
Fluor 594 donkey anti-mouse (Invitrogen, Paisley, UK) secondary antibody, as described [17].
Coverslips were mounted onto slides in VECTASHIELD1 mounting medium with DAPI
(Vector laboratories, Peterborough, UK) and visualized by confocal microscopy using a Leica
TCS SP5 confocal system, attached to the DMI 6000 microscope [17].
Plasma biochemistry
Blood samples were collected from the retro-orbital veins [23] following terminal anaesthesia,
and plasma was separated by centrifugation at 3000g for 5 minutes at 4˚C. Plasma samples
were analysed for total calcium, inorganic phosphate, alkaline phosphatase, albumin, urea, cre-
atinine and glucose, using a Beckman Coulter AU680 semi-automated clinical chemistry ana-
lyzer, as described [24]. Plasma calcium was adjusted for variations in albumin concentrations
using the formula: ((albumin-mean albumin) x0.02) + calcium) [24].
Histology and immunohistochemistry
Dissected bones were fixed in 10% formalin and decalcified in formical-4™ (Decal Chemical
Corporation) for 3 days before embedding in paraffin wax [17]. Bone sections (3–4μm) were
stained with Alcian blue 8GX and van Gieson [17]. For immunohistochemical analysis,
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dewaxed sections were treated with proteinase K for antigen retrieval, before staining with rab-
bit polyclonal phospho-p38 MAPK (cat # 4631) and phospho-MKK3/MKK6 (cat # 9231) anti-
bodies (Cell Signalling Technology, Danvers, USA) using the ABC staining system (Santa
Cruz Biotechnology, Santa Cruz, USA). Digital images were obtained using the Nanozoomer
2.0 Digital Pathology system (Hamamatsu Photonics, Welwyn Garden City, UK).
Statistical analysis
Mean values and standard deviations (SD) or standard errors of mean (SEM) were calculated
and analysis performed using unpaired Student’s t-test for independent samples [19]. The
Bonferroni correction for multiple testing was applied [19].
Results
Identification of kyphosis (KYLB) mice
A dysmorphology screen of 10 day old mice revealed that a number of G3 progeny from an
ENU-mutagenized BALB/c male mouse had developed curvature of the vertebral column, and
these were designated KYLB. Radiography of 8 week old KYLB mice revealed that the vertebral
column deformity was due to a thoraco-lumbar kyphosis (Fig 1A) and the severity of the
kyphosis was similar in male and female KYLB mice. KYLB mice were observed to have a nor-
mal gait without any overt neurological or muscular abnormalities. Alcian blue and Alizarin
red S staining to visualize cartilage and bone, respectively, in the skeletons of 4 week old mice
confirmed the presence of the thoraco-lumbar kyphosis (Fig 1B). In addition, the KYLB mice
were observed to have longer bodies (Fig 1B), an increased length of the vertebrae (Fig 1C)
and lengthened long bones (Fig 1D), when compared to their unaffected littermates. The sizes
of the calvarial bones were not overtly different in KYLB mice. Breeding of KYLB mice with
normal BALB/c mice, and intercrossing the offspring yielded ~23% affected KYLB mice (8
affected (4 males, 4 females) and 27 unaffected (10 males, 17 females)), which is consistent
with the expected ~25% of mutants for an autosomal recessive disorder. Thus, KYLB mice rep-
resent a model for autosomal recessive thoraco-lumbar kyphosis.
Mapping of the Kylb locus to chromosome 15A1 and identification of an
Npr3 missense mutation
Genome-wide analysis using DNA samples from 22 KYLB mice and 91 SNPs mapped the Kylb
locus to a 5.5Mb region on chromosome 15A1 flanked centromerically by rs13459145 and tel-
omerically by rs13482436 (Fig 2A). This interval contains 51 genes, including the Npr3 gene,
mutations of which have been previously reported to be associated with kyphosis in mice [21,
22, 25]. DNA sequence analysis of the Npr3 gene in affected mice was therefore undertaken,
and this identified a homozygous T to A transversion at codon 209, which altered a tyrosine
(Tyr) residue to an asparagine (Asn) residue (Fig 2B). The T to A transversion also generated a
Tsp509I restriction endonuclease recognition site that was used to confirm the missense muta-
tion by restriction endonuclease analysis (Fig 2C). Thus, all the affected KYLB mice were
homozygous for the mutation (Kylb/Kylb), whilst unaffected mice were either wild-type (+/+)
or heterozygous (Kylb/+) (Fig 2C). The mutated nucleotide has a PhyloP score of 2.69, indicat-
ing conservation of the nucleotide, and an amino acid sequence alignment of eukaryotic NPR3
homologs revealed that the Tyr209Asn NPR3 mutation alters an evolutionarily conserved
tyrosine residue (Fig 2D). Furthermore, the Tyr209Asn mutation introduces a consensus
N-linked glycosylation site (N-X-T) of 209Asn-Phe-Thr211 into the mutant NPR3 protein
(Fig 2D).
Mouse Model for Kyphosis with NPR3 Mutation and MAPK Pathway Activation
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Functional characterization of mutant Npr3
NPR3 is a type 1 transmembrane protein consisting of a large extracellular domain (476
amino acids), a transmembrane domain (23 amino acids) and a short cytoplasmic domain
(37 amino acids) [26], and acts as a decoy receptor for C-type natriuretic peptide (CNP)
[27]. The extracellular domain of NPR3 is predicted (NetNGlyc 1.0 Server) to have two con-
sensus sites for N-linked glycosylation (N-X-S/T) at amino acids 81–83 and 389–391. To
investigate the functional consequences of the Tyr209Asn NPR3 mutation and to assess the
novel putative N-linked glycosylation site, EGFP-tagged wild-type (Tyr209) and mutant
Fig 1. Phenotypic features of KYLB mice. (A) Radiography of adult (8 week old) male KYLB and unaffected male
littermate. The KYLB mouse has kyphosis of the thoraco-lumbar spine. (B-D) Alcian blue (cartilage) and Alizarin red (bone)
staining of young (4 week old) male KYLB and male unaffected mice. KYLB mice had longer bodies (B), vertebrae (C), and
lengthened long bones (tibia shown) (D), when compared to unaffected littermates.
doi:10.1371/journal.pone.0167916.g001
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Fig 2. Mapping of Kylb locus and identification of Npr3 mutation. (A) The Kylb locus, which originated in a BALB/c
ENU-mutagenised male mouse and was hence inherited with the BALB/c alleles, was mapped to a 5.5Mb region
flanked by the SNPs rs13459145 and rs13482436 on chromosome 15A1 containing 51 genes, including the most likely
candidate, Npr3. (B) DNA sequence analysis of the Npr3 gene revealed a T to A transversion at codon 209 in exon 1,
altering the wild-type (WT) sequence TAT, encoding tyrosine (Tyr), to the mutant (m) sequence AAT, encoding
asparagine (Asn). The mutation introduced a Tsp509I restriction endonuclease site (/AATT) and this was used to
confirm the mutation. (C) PCR primers specific for exon 1 were designed to amplify a 325bp product. Tsp509I did not
cleave the WT PCR product but did cleave the mutant PCR product to yield 262bp and 63bp products, as shown by
agarose gel electrophoresis of the digested Tsp509I PCR products. KYLB mice were homozygous for the mutant
262bp and 63bp (not shown) products (Kylb/Kylb), whilst unaffected mice were either homozygous for the 325bp
product (WT, +/+) or heterozygous for the wild-type and mutant products (Kylb/+). (D) Protein sequence alignment
(CLUSTALW) of NPR3 from 4 species revealed that the Tyr (Y) residue is evolutionarily conserved in the NPR3
homologs in mouse, human, monkey and zebrafish. Furthermore, the Asn209 (N) mutant (asterisk) generates a
consensus N-linked glycosylation site (N-F-T) (indicated by horizontal line).
doi:10.1371/journal.pone.0167916.g002
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(Asn209) Npr3 cDNA constructs were transfected into COS-7 cells and their expression and
subcellular localization assessed. In addition, the in vitro consequences of two other ENU-
induced NPR3 missense mutations, His168Asn [21] and Ile384Phe [22] that were reported
to be associated with kyphosis in Strigosus (Stri) and Eel mice, respectively, but whose cellu-
lar effects were not reported, were similarly assessed (Fig 3). Interestingly, the Asn168 NPR3
mutant is also predicted to generate a novel N-linked glycosylation site (168Asn-Leu-Thr170
(168N-L-T170)). Western blot analysis of cell lysates obtained from COS-7 cells transiently
transfected with wild-type or mutant EGFP-tagged constructs revealed that the Asn168 and
Asn209 NPR3 mutants were associated with the presence of a higher molecular weight prod-
uct of ~89kDa compared to the wild-type and mutant Phe384 NPR3 proteins at ~87kDa (Fig
3A), suggesting that the mutant Asn168 and Asn209 amino acid residues were glycosylated.
Treatment of transfected cell lysates with the deglycosylating enzyme, Endo H, which cleaves
high mannose N-linked glycans that are introduced in the endoplasmic reticulum (ER),
revealed the presence of Endo H-sensitive products in all the cell lysates (Fig 3B), thereby
indicating that the wild-type NPR3 and the three mutant (Asn168, Asn209 and Phe384)
NPR3 proteins all had high mannose structures, and that all of them had entered the ER
lumen. However, lysates from cells expressing wild-type NPR3 protein also had Endo H-
resistant products, which were not present in lysates from cells expressing the mutant
(Asn168, Asn209 and Phe384) NPR3 proteins (Fig 3B). This suggested that the mutant
Asn168, Asn209 and Phe384 NPR3 proteins did not undergo the complex oligosaccharide
modifications that occur in the Golgi apparatus, but may instead be retained in the ER.
Immunofluorescence and confocal microscopy studies of the transiently transfected COS-7
cells confirmed this prediction. Thus, wild-type NPR3 protein was predominantly located at
the plasma membrane, with some wild-type NPR3 protein also located in the Golgi appara-
tus, which was indicated by co-localization with the Golgi-matrix protein, GM130 (Fig 3C).
By contrast, the mutant Asn168, Asn209 and Phe384 NPR3 proteins were mislocalized and
retained in the ER (Fig 3D), as indicated by co-localization with protein disulphide isomer-
ase (PDI) (Fig 3D).
Phenotyping and clinical chemistry analysis of 12 week old wild-type,
Kylb/+ and Kylb/Kylb mice
Kylb/+ mice were intercrossed to generate wild-type, Kylb/+ and Kylb/Kylb mice. The
crown to rump length of Kylb/Kylb male and female adult mice, aged 12 weeks, was ~12%
greater than that of the Kylb/+ and wild-type littermates (p<0.01), although the body
weights were similar in Kylb/Kylb and wild-type littermates (Table 1). Femoral lengths in
Kylb/Kylb mice were greater than 2 standard deviations longer than unaffected (wild-type
and Kylb/+) littermates (S1 Fig). Whole body DXA analysis revealed that Kylb/Kylb mice,
when compared to Kylb/+ and wild-type littermates, had significant increases in bone area
by ~22% (p<0.001) in females and ~12% (p<0.05) in males, increased bone mineral content
by ~18% (p<0.05) in females, and reduced percentage body fat by ~28% (p<0.05) in females
(Table 1). Plasma biochemical analysis of 12 week old wild-type (males n = 8 and females
n = 8), Kylb/+ (males n = 13 and females n = 13) and Kylb/Kylb (males n = 7 and females
n = 4) mice did not reveal any alterations in the levels of urea, creatinine, calcium, phos-
phate or albumin (S1 Table). However, female, but not male Kylb/Kylb mice had signifi-
cantly elevated alkaline phosphatase (ALP) levels (mean ± SD = 127 ± 21 U/l, p<0.05)
compared to Kylb/+ (98 ± 12 U/l) and wild-type littermates (93 ± 15 U/l), suggesting
increased bone turnover.
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Fig 3. Expression and localization of wild-type and His168Asn, Tyr209Asn and Ile384Phe NPR3 proteins in COS-7 cells. (A)
Western blot analysis of cell lysates from COS-7 cells transfected with either the wild-type (WT) or mutant (Asn168, Asn209, or Phe384)
EGFP-tagged constructs. The WT and mutant Phe384 NPR3 proteins had molecular weights of 87kDa, whilst the Asn168 and Asn209
NPR3 mutants had a higher molecular weight of 89kDa, consistent with glycosylation at the mutant Asn168 and Asn209 residues. (B)
Treatment with Endo H revealed some undigested WT NPR3 protein products whereas all the mutant NPR3 proteins were Endo H-
sensitive, suggesting retention in the endoplasmic reticulum (ER). Tubulin was used as a loading control. (C-D) COS-7 cells transiently
expressing EGFP-tagged WT or mutant (Asn168, Asn209 and Phe384) NPR3 proteins (green) were counterstained with anti-GM130
antibody (red) which is specific for the Golgi apparatus (C), or anti-PDI antibody (red) which is specific for the ER (D), and DAPI (blue) which
is specific for nuclei. WT NPR3 localised to the plasma membrane with some expression in the Golgi apparatus, whereas all the mutant
NPR3 proteins co-localised with the ER marker (orange). Scale bars = 20μm.
doi:10.1371/journal.pone.0167916.g003
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KYLB mice have delayed endochondral ossification and increased
activation of p38 mitogen-activated protein kinase (MAPK) signaling
To investigate the basis of the greater lengths of the vertebrae (Fig 1C) and long bones (Fig 1D)
in Kylb/Kylb mice, lumbar vertebral (Fig 4A and 4B) and tibial (Fig 4C and 4D) sections from
1 day old mice were stained with Alcian blue which stains cartilage blue, and van Gieson
which stains osteoid in the bone matrix red. Bone matrix formation was observed to be promi-
nent in the central region of lumbar vertebrae in wild-type mice, but was deficient in Kylb/
Kylb mice, in whom the central region mainly consisted of cartilage (Fig 4A). The hypertrophic
zone (HZ) in Kylb/Kylb mice was expanded ~2-fold in the vertebrae (Fig 4B). Similarly, in the
tibiae of Kylb/Kylb mice the HZ was expanded when compared to those from wild-type mice
(Fig 4C and 4D). Thus, there is likely a delay in endochondral ossification in the vertebrae and
tibiae of Kylb/Kylb mice. NPR3 is a decoy receptor for C-type natriuretic peptide (CNP), and
functional loss of NPR3 may result in increased CNP signaling [25]. CNP-stimulated expan-
sion of the hypertrophic zone of the growth plate in a tibia organ culture system has been
reported to be dependent on the activation of the p38 mitogen-activated protein kinase
(MAPK) signaling pathway [27], and we therefore explored the role of the p38 MAPK signal-
ing pathway in causing the expansion of the vertebral growth plate. Immunohistochemical
analysis of lumbar vertebral sections from 1 day old mice to detect phosphorylated (active) p38
MAPK revealed that Kylb/Kylb mice, when compared to wild-type littermates, had an increase
in phosphorylated p38 MAPK in the resting, proliferative and hypertrophic zones, but not
bone matrix, of their vertebrae (Fig 5). Furthermore, phosphorylation of the upstream activa-
tors of p38 MAPK, MAPK kinase 3/ MAPK kinase 6 (MKK3/MKK6) was also increased in the
resting, proliferative, and hypertrophic zones in vertebrae of Kylb/Kylb mice compared to
wild-type littermates (Fig 5). Thus, there is an increased activation of the p38 MAPK signaling
pathway in Kylb/Kylb vertebrae.
Discussion
We have established an ENU-induced mutant mouse model, KYLB, for autosomal recessive
kyphosis due to a novel Tyr209Asn mutation in NPR3. In addition, our studies have revealed
that this Tyr209Asn NPR3 mutation generates a new N-linked glycosylation site, which is
Table 1. Body weight, length and DXA analysis of 12 week old mice.
Females Males
Wild-type (n = 6) Kylb/+ (n = 11) Kylb/Kylb (n = 7) Wild-type (n = 7) Kylb/+ (n = 11) Kylb/Kylb (n = 4)
Body weight (g) 23.7 ± 1.7 24.5 ± 2.9 23.7 ± 1.4 30.5 ± 1.5 32.3 ± 2.5 31.5 ± 2.5
Body length (cm)a 9.1 ± 0.4 9.3 ± 0.2 10.2 ± 0.2$ 9.5 ± 0.2 9.9 ± 0.4 10.6 ± 0.5**
Bone area (cm2) 8.3 ± 0.6 8.7 ± 0.8 10.1 ± 0.4$ 9.0 ± 0.4 9.4 ± 0.6 10.1 ± 0.7*
BMC (mg) 413 ± 44 430 ± 51 488 ± 22* 493 ± 38 517 ± 44 513 ± 60
BMD (mg/cm2) 49.6 ± 2.1 49.2 ± 2.0 48.2 ± 1.9 54.9 ± 2.9 55.1 ± 1.9 50.9 ± 3.0
Lean mass (g) 18.3 ± 1.0 18.6 ± 1.7 18.8 ± 1.1 24.5 ±1.4 25.0 ± 1.8 25.3±1.9
Fat mass (g) 4.5 ± 1.1 5.1 ± 1.6 3.1 ± 0.9 3.8 ± 1.0 5.1 ± 1.7 4.9 ± 0.4
Fat content (%) 19.4 ± 3.5 21.3 ± 5.2 13.9 ± 2.8* 13.4 ± 2.4 16.6 ± 4.1 16.3 ± 1.2
Values are expressed as mean ± SD.
a Body length measured from crown to rump. BMC, bone mineral content; BMD, bone mineral density.
*p<0.05,
**p<0.01,
$p<0.001.
doi:10.1371/journal.pone.0167916.t001
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utilised and results in the ER retention of the mutant NPR3 protein. Finally, our investigation
shows that the kyphosis, due to lengthening of vertebrae, is associated with a delay of endo-
chondral ossification and activation of the p38 MAPK signaling pathway. Interestingly, this
did not prevent KYLB mice from attaining a normal BMD by the age of 12 weeks, indicating
that the process of endochondral ossification was not defective in KYLB mice but only
delayed.
The phenotypic features of the KYLB mouse have both similarities and differences com-
pared to the other 5 mouse models due to NPR3 abnormalities that have been previously
described (Table 2). These mouse models are: a Npr3 null mouse generated by homologous
recombination [25]; two spontaneously occurring models referred to as Longjohn (Lgj) and
Longjohn-2J (Lgj2J) [21], which are due to a 36bp in-frame deletion and a nonsense Gln95Stop
NPR3 mutation, respectively; and two ENU-induced mutations, referred to as Strigosus (Stri)
Fig 4. Histomorphometric analysis of vertebral and tibial growth plates. Alcian blue and van Gieson staining of lumbar vertebrae (A, B)
and tibiae (C, D) from 1 day old male mice showing reduced bone matrix (BM) formation (red stain) between intervertebral discs (IVD) and
distal tibia in Kylb/Kylb mice compared to wild-type (WT) littermates. White boxes delineate detailed views shown in (B) and (D) of growth
plates, showing expansion of the hypertrophic zone (HZ) in Kylb/Kylb mice compared to WT littermates. The resting (RZ) and proliferative
(PZ) zones in the Kylb/Kylb and WT mice appeared to be similar and not affected. Scale bars = 100μm (A); 50μm (B, D); 200μm (C).
doi:10.1371/journal.pone.0167916.g004
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Fig 5. p38 MAPK signaling in vertebral growth plates. Vertebral sections from 1 day old wild-type (WT) and
Kylb/Kylb male mice were stained with antibodies against phosphorylated p38 MAPK and MKK3/MKK6.
Vertebrae from Kylb/Kylb mice had increased staining in the resting (RZ), proliferative (PZ) and hypertrophic
(HZ) zones, but not in the bone matrix (BM), when compared to vertebrae from WT littermates. Scale
bars = 50μm.
doi:10.1371/journal.pone.0167916.g005
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[21] and Eel [22] which are due to His168Asn and Ile384Phe NPR3 missense mutations,
respectively. Similarities between KYLB mice and previously reported models include the
occurrence of kyphosis and lengthening of the body and long bones. However, there are also
important differences, which include: the occurrence of arachnodactyly in the Lgj, Lgj2J and
Stri models [21]; sacral/tail kinks in the Lgj, Lgj2J, Stri and Npr3 null mice [21, 25]; and prema-
ture death in Lgj2J and Npr3 null mice [21, 25]. In addition, vertebral enlargement, which was
present in KYLB mice (Fig 1C), was reported in Stri mice, but not in the other models; and
delayed endochondral ossification, which was found in KYLB mice (Fig 4), was reported in
Stri and Npr3 null mice, but not in the other models (Table 2). The basis of these differences
may in part be due to the intracellular effects of the NPR3 mutant proteins, and this is well
illustrated by our in vitro expression studies of the three NPR3 missense mutants, which
revealed that the Asn168 and Asn209 mutations resulted in abnormal N-linked glycosylation
with ER retention, whereas the Phe384 mutation was not associated with abnormal N-glyco-
sylation but was retained in the ER. Thus, these three missense NPR3 mutant proteins would
result in defective trafficking and an absence of functional NPR3 at the plasma membrane, a
situation that is also likely to be the case in the Npr3 null mice. This may help to explain the
close similarities in the phenotypes of these mutant mice (Table 2). In contrast, it has been
reported that the 12 amino acid in-frame deletion giving rise to Lgj may result in defective
ligand binding capability of the mutant proteins at the plasma membrane [21], and this may in
part explain the phenotypic differences between the Lgj mouse and the KYLB, Stri and Npr3
null mice. During the course of our studies, another model of kyphosis designated Skm1, due
to an Ile384Asn NPR3 mutation was reported [28] (Table 2); however the Asn384 mutation
does not introduce a consensus N-linked glycosylation site, similarly to the Eel NPR3 muta-
tion, and thus is likely to be retained in the ER but without abnormal N-linked glycosylation.
Further characterisation of the bone alterations in KYLB mice by DXA analysis revealed an
increase in bone area, which was associated with a corresponding increase in bone mineral
content only in females. These changes were not reported in any of the Stri, Lgj, Lgj2J, Npr3
Table 2. Comparison of mouse models with kyphosis due to Npr3 mutations.
Mouse model Stri Lgj Lgj2J Npr3 null Eel Skm1 KYLB
Derivation ENU SPO SPO HR ENU ENU ENU
Mutation His168Asn 36bp del Gln95Ter Del exon1 Ile384Phe Ile384Asn Tyr209Asn
Phenotypic features
Kyphosis + + + + + + +
Elongated body + + + + + + +
Elongated long bones + + + + + + +
Enlarged vertebrae + ? ? ? ? ? +
Blood pressure ? ? ? reduced ? + ?
Urine concentration ? ? ? reduced ? + ?
Delayed endochondral ossification + ? ? + ? - +
Arachnodactyly + + + ? ? ? –
Sacral/tail kinks + + + + ? ? –
Premature death ? – + + ? ? –
Fate of mutant NPR3 ER retained* ? ? absent ER retained* ? ER retained*
Reference [21] [21] [21] [25] [22] [28] This study
SPO, spontaneous; HR, homologous recombination; Del, deletion;?, unknown; +, present;–, not present;
*, reported in this study
doi:10.1371/journal.pone.0167916.t002
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null, Eel or Skm1 mouse models. The reason for the gender-specific differences in some of the
bone parameters in female but not male KYLB mice remains to be elucidated; however, other
mouse models for skeletal disorders have also demonstrated gender-specific effects [17].
The absence of functional NPR3 at the plasma membrane may help to explain the
observed delay in endochondral ossification that likely involves increased activation of the
p38 MAPK signaling pathway. Thus, NPR3, which has a wide tissue expression pattern
including chondrocytes [29] and likely functions as a clearance receptor for natriuretic pep-
tides [30], has emerged as a key regulator of endochondral bone growth through its action on
locally produced CNP [27, 29]. Binding by CNP to its receptor, NPR2 [31], stimulates endo-
chondral ossification and bone growth likely by actions on hypertrophic chondrocytes,
which include an increase in their production and a delay in their replacement with bone
[27]. Indeed, in vitro studies have demonstrated that CNP can stimulate longitudinal growth
of cultured mouse tibiae [27], and that these effects are mediated by the p38 MAPK signaling
pathway [27, 32]. Furthermore, in vivo studies have shown that: dwarfism occurs in CNP-
deficient mice [29], and in mice and patients with Npr2 mutations [33, 34]; mice overexpres-
sing CNP have skeletal overgrowth [35]; targeted overexpression of CNP in chondrocytes
can rescue dwarfism in a mouse model of achondroplasia, through a MAPK-dependent path-
way [36]; and genome-wide association studies in humans have identified significant associa-
tions between the CNP signaling pathway and measures of height and skeletal size [37, 38].
Thus, these in vitro and in vivo findings demonstrate an important role for CNP and NPR2 in
activating MAPK signaling and in delaying hypertrophic chondrocyte replacement by bone
matrix [27] (Figs 4 and 5). Within this scheme, the role of NPR3 is to act as a decoy receptor
that binds CNP and promotes its internalization and degradation, thereby reducing the bio-
availability of CNP and hence its stimulatory effect on endochondral bone growth [39]. Thus,
mutations of NPR3, which prevent its appearance at the plasma membrane (Fig 3C), will
result in decreased clearance of CNP, leading to increased activation of p38 MAPK signaling,
as demonstrated by our observations of an increased expression of phosphorylated MKK3/
MKK6 and p38 MAPK in the vertebral growth plates from KYLB mice (Fig 5). We therefore
propose a molecular and cellular model (Fig 6) to explain the kyphosis that results from the
NPR3 mutation in the KYLB mice, as follows. In the hypertrophic chondrocytes of wild-type
mice, NPR3 is synthesised in the ER, post-translationally modified with high mannose N-
linked glycans, and transported to the Golgi whereby it undergoes further processing with
addition of complex oligosaccharides residues. The mature NPR3 is then transported to the
plasma membrane where it both terminates p38 MAPK signalling in the hypertrophic chon-
drocytes, and regulates the availability of CNP to signal through the MKK3/MKK6 and p38
MAPK signaling pathway in resting and proliferating chondrocytes. However, in the hyper-
trophic chondrocytes of KYLB mice, mutant NPR3 is synthesised in the ER and post-transla-
tionally modified with high mannose N-linked glycans, but is not transported to the Golgi
apparatus or the plasma membrane. Thus, uncleared CNP is available to bind to NPR2 and
persistently stimulate p38 MAPK signaling in resting, proliferative and hypertrophic chon-
drocytes, thereby delaying bone matrix formation from hypertrophic chondrocytes, whose
enhanced survival results in a longer period of growth and elongated bones. With the excep-
tion of mice overexpressing CNP [35], the other reported mouse models for kyphosis do not
appear to have the same pathogenesis as mice with mutations in Npr3, further emphasizing
the multiple etiologies of kyphosis.
In conclusion, we have established a novel mouse model for kyphosis associated with
lengthened vertebrae and long bones that harbors a Tyr209Asn mutation in NPR3. Vertebrae
in KYLB mice demonstrated delayed ossification, likely due to increased activation of the p38
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MAPK pathway that is activated by CNP. This is consistent with the role of NPR3 as a decoy
receptor for CNP and our studies have further elucidated the role of CNP and NPR3 in endo-
chondral ossification.
Supporting Information
S1 Fig. Femoral lengths in 12 week old mice. Femoral lengths of 4 week old wild-type (WT),
Kylb/+ and Kylb/Kylb male and female mice. Femora from Kylb/Kylb mice were more than 2
standard deviations (SD) longer than those from unaffected (WT and Kylb/+) mice. Individual
squares (males) and circles (females) represent individual mice; the bars represent the mean ±
SD of unaffected mice. Open symbols represent WT mice, gray symbols represent Kylb/+
mice, and black symbols represent Kylb/Kylb mice.
(TIF)
S1 Table. Plasma biochemical analysis of 12 week old wild-type, Kylb/+ and Kylb/Kylb
mice. Values are expressed as mean ± SD. Corr. Ca: corrected calcium; Pi: inorganic phos-
phate.
(DOCX)
Fig 6. Schematic model illustrating the role of NPR3 as a decoy receptor. In wild-type (WT) chondrocytes, NPR3 binds CNP thereby
promoting its internalization and degradation, and reducing its availability to bind to NPR2 to stimulate the MAPK signaling pathway, whose
activation inhibits termination of hypertrophic chondrocytes (HC) and bone formation. In KYLB mice who have a homozygous Tyr209Asn
NPR3 mutation, NPR3 is abnormally glycosylated and retained in the ER. The absence of NPR3, and its loss as a decoy receptor for CNP,
results in a greater availability of CNP to bind to NPR2, leading to increased MAPK signaling and enhanced survival of hypertrophic
chondrocytes, resulting in the lengthening of bones.
doi:10.1371/journal.pone.0167916.g006
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